Anti-Human CD279 (PD-1) (Nivolumab) - Dylight® 488
Catalogue Number: LT1211-LET
| Manufacturer: | Leinco Technologies, Inc |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | |
| Clone: | 5C4.B8 |
| Isotype: | |
| Immunogen: | |
| Application: | FC, IHC, FA |
Description
Description: Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
Additional Text
Concentration
0.2 mg/ml
Antibody Clonality
Monoclonal, Recombinant Monoclonal
Storage Note
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations